SNSS - Earnings call transcript Q4 2019 | Viracta Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to Sunesis Pharmaceuticals fourth quarter and year-end 2019 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker presentation there will be a question-and-answer session. [Operator Instructions]. Please be advised that today's conference is being recorded. Instructions]. [Operator

ahead. like Quinn, conference Senior Chief Corporate Please now speaker, to Vice hand Development. Willie Mr. Financial go to would over the your President, I Officer and

Willie Quinn

us. our corporate Welcome Vice Dayton With on Interim everyone more President, and Executive Fox, President, Commercial. Executive Judy events, will will provide provide Scientific Officer, you details Par Research and for & Chief me are Development, Judy Dayton I thank will today pipeline brief fourth Misfeldt, Officer, Vice recent overview financial Chief review quarter joining Hyare, Senior XXXX. a of

We questions for will which available. call be all then open the we for will

in company's let will forth beliefs concerning intentions, conference me begin, statements actual to that you future call, events. discussed could we These differ be during of press qualified set materially statements we the SEC, accurate forward-looking factors intend forward-looking by important is we today's release the expectations Before which making today those forward-looking filings are with as in and or and do remind represents results to the today's today's that call such not cause update. statements. company's from on Information

Dayton. me With call that, turn over let to the

Dayton Misfeldt

Willie. Thanks us. and for you joining afternoon Good thank

have our to in product We made XXXX across progress worked build portfolio. value significant as we

track dose For second this vecabrutinib, complete the Xb the cohort portion escalation our trial are to Phase noncovalent the BTK the of on inhibitor, and we seventh are in portion in the quarter. in trial of we

economic lastly, developing pan-Raf through we ended inhibitor for milestones. end which an of interest. our with portfolio million we our inhibitor And with the by sufficient to PDKX towards the first-in-class filing a We for topo advance year. partners $XX.X important II IND TAK-XXX, retain new inhibitor have cash, and SNS-XXX, continue in We to a vosaroxin, clinic advance XXXX this AML targeted downstream

activity in combined in safety tumor improvement patient BTK without of patients eight. milligram to CXXX-mutations. clinical burden evidence a with XXX very now continued In CLL with continue in of we vecabrutinib, saw favorable and cycle the and study reduction see profile For we cohort, on still a

first initial expect for milligram complete second assessments assessments quarter. XXX the month have cohort to will response milligram for and response in this XXX cohort We the the

We the X are the dose. prepared to Phase once trial have begin we identified recommended

seeing to However, next we future efficacy signal. after will steps. evaluating look in near X from start forward seven We a only cohorts determine six Phase the data and to sufficient the

pipeline. would to do the I detail will highlight our with bit before progress the PDKX Judy made further inhibitor, a SNS-XXX. our turn But so, I proprietary call in provide over I to like to recent

triple data generating are and program. We combination we the This the exciting drug data activity SNS-XXX month, presented cancer hematologic meeting, we models showing tumor at study this In from conference. indicating October, synergistically AACR-NCI-EORTC several encouraging with classes. received encouraging vitro results on in preclinical can combine solid in an that

are by SNS-XXX to end the completing studies with target IND-enabling of a XXXX. IND file We for an

pipeline through product SNS-XXX, also partnerships. our creating and value are vecabrutinib Beyond in we

assets. focus company excited pleased The progresses. and their potential agreements are proprietary two to TAK-XXX our drugs revenue We licensing these improving are our both generated look on as development to companies cash about that for licensed watching now to forward vosaroxin and the our while pipeline the adding

to over into current go With our detail I will on progress. turn to the Judy more that, call clinical

Judy Fox

Thanks Dayton.

on three in Currently, will disease the cohort XXX, In presented have and seventh in Phase December, of in three currently clinical are showing XXX patients milligrams. quarter. of at trial XXX in cohorts, and ASH evidence are across that five the milligram response assessments treatment this of stable the We see patients eight We Xb the of data the XXX month cohort data continued vecabrutinib. milligram benefit milligram cohort. we been next XXX XXX and from cohort the observed has

in one scan, with parameters from reduction. today, at CLL reduction cohort of their normalized. burden eight have on patient As XX% tumor improving remains from their study initial in second Their XX% a cycle hem this

Another grade higher patient zone progression. to very patient prior events from coming heavily lymphoma cohorts eight have levels higher of seen with milligram well the and in has a XXX dose a above nine drug-related the XX off-study pretreated cohort, adverse been in three due lines before or completed not tolerated therapy any disease day. marginal cycles milligrams Vecabrutinib

and consistent. We have increase in decreases exposure cytokine in remains seen incremental

three cohort, milligram XXX patients the was DLBCL be assessments disease this CLL one. patients, three to remain on their The due and six, one results and we four cycle CLL response progression first will enrolled cohort with of treatment In month. later available nonevaluable with DLBCL. during

and cleared cohort have patients XXX with with In progression the cohort, Two and seven, safety six four CLL CLL two including on remain milligram lymphoma. treatment patients the treated treatment disease patients with mantle two cell period. are off all evaluation

CAR-T Nonclinical We have in for dual an vecabrutinib expect are in patients ongoing. of response cell engager to of enhancer the potential assessing additional evaluated of by assessments are as first effect patients inhibition and Vecabrutinib virtue therapy second combination cohort. therapies these quarter for and patients studies its being with BTK the may the ITK. also

therapy ITK combination Blinatumomab, nonclinical engager, and in improved outcomes CLL has enhanced shows CLL in with vivo. inhibits patient bispecific and Ibrutinib clinical BTK of CAR-T T-cell studies of to also activity clinically ex which patients samples a Ibrutinib, the shown

SNS-XXX. or CDKNXA many with XXX. the to data were to deletions we gene tumors poster Turning sensitive particularly and are presented mutations types. cancer associated in mutations in highlighted different October CDKNXA The showing that deletions with

cancer synergistic the with cell engager cell GXXC combination lines. in and profiled KRAS learned cancer SNS-XXX KRAS-mutant in combined lines CDKX/X, in with lymphoma We agents other current of inhibitors also or when exhibits BCLX and breast that activity

hematologic clinical define solid for program we and the with are progressing We both SNS-XXX our IND-enabling plans through tumor discussions are in as and KOLs malignancies.

Willie results. financial call I turn to review over to will now the

Willie Quinn

XXXX. $X.X fourth on year the from our In solid delivered within progress in compared million, for for $X.X the million end of cash Judy. compared was quarter for cash, for million Loss and you equivalents XXXX, in restricted and we quarter, used marketable was the $XX.X securities million while vecabrutinib $XX.X was the $XX.X million XXXX, At SNS-XXX and to $XX.X for including operating to Thank $XX.X cash operations operating it budget. Total XXXX. million million, totaled cash. activities

up $XX agreement with and agreement or agreement, TAK-XXX. million fee the new DOT-X. of additional agreements As Sunesis TAK-XXX partners a precommercial and entered we plus royalties with consented to and Under to DOT upfront Sunesis signed DOT-X In payments into an transaction, agreed TAK-XXX Takeda to million our of to venture mentioned, the pan-Raf this covering Coincident DOT-X December, pay Therapeutics-X to Dayton milestone in on also vosaroxin. paid inhibitor of startup future both develop TAK-XXX. $X covering sales backed assignment Oncology's we new

sales company double Also in Under are upfront biomarker terms of digit future in to million December, $XX we royalties agreement, the of commercial licensed received to vosaroxin. development. held vosaroxin we a the to with to up Denovo milestones regulatory plus and payment and a receive privately on million Biopharma, eligible approach biopharmaceutical a $X.X

your that, Operator? With open the let's questions. call to

Operator

Instructions]. [Operator

Please with ahead. Hartaj from comes go Oppenheimer. Singh question first Our

Hartaj Singh

for Thank you. good progress. Thanks Great. and questions the

my Just a couple of questions on end.

I BID four patients screened the I XXX there mentioned you And cohort. were right, for But that there evaluated mentioned cohort. had six left. Is each think for you had six. being milligram that, had there's still think additional You were slots,

you Or be have So add add two amended more the at to are you that? to be to able patients? able just protocol to going more

Judy Fox

Good Thanks Hartaj. question.

that requested allowed treatment were us review requested, patients the additional to we investigators put basically that in And our protocol. on. They they consider and these committee they said our So who patients had safety require patients. interested

essentially, the are cohort. we so And over-enrolling

Hartaj Singh

a Dayton to Thank any I upper fair Does Great. study have also BID should second escalation this Or Judy. see efficacy? go that by and be test you be that for you dose the going amendment you the include are Judy, part to think higher a to thoughts any you over is terms year. of limit that mentioned you will or of the in of -- milligram know to said, thoughts, maybe protocol of vecabrutinib XXX quarter doses?

Judy Fox

Yes.

its We something it's consider. data in at totality will that and we can the look

Hartaj Singh

Great.

you think into expansion, go year, in just Okay. say, the dose you next just of of, of just assuming steps terms you on the are the dose you of broadly sites, you types can Xb/X in you that whole what terms of expect Just expansion let's pass broadly, towards quarter patients? can study? XXXX? this the if of Judy, the if kind to playing out rest expansion the dose steps about not you from walk were Also, just through just and end the going that of from to number for see escalation How part of the happen second the but us study patients, expand escalation forward the Phase

Judy Fox

Yes.

there ASH patients that inhibitor at inhibitor was for prior the then BTK X study. are patients. that presented It patients total cohort with Phase in cohorts therapy we a without covalent So different are CXXX mutation. design and at intolerant and that planned BTK study And our looking are December, number therapy. of patients XXX relapsing the of And to from

Hartaj Singh

tumors that be Judy, then you looking it I question would And last in know, from solid me at just liquid and tumors. Understood. it. is both Got on mentioned SNS-XXX. had you

any versus versus then healthy there? in studies a Just solid you Just volunteers thoughts? Phase should or the expect combo? Phase X combination any would do classics right off mono go into initial in Or thoughts begin? we So tumors to liquid Ib/X and

Judy Fox

Yes.

So the development that would and necessarily with subject out you combination therapy. with would but plan into not lead beginning monotherapy study our healthy fleshing the we stages clinical are then typically start in of

still, to tumor in solid but and are developing mentioned, malignancies. do I we So both expect our execute plans hematologic as studies

Hartaj Singh

than with. of my mechanism action sticks last you more others? Is that any just And there Great. one that out question synergize the just various

Judy Fox

It's early think saw. encouraged the days. by And we that are I quite data we

sets, we up vivo what expect on in Moving we mechanism studies with combination what in the basically of in would were to encouraged with studies we But on following in the course, PDK see vitro saw without data vitro. further studies.

Hartaj Singh

you Great. Thank for question. all the

Looking forward to more data.

Judy Fox

Thanks.

Dayton Misfeldt

Hartaj. Thanks

Operator

you. Thank

Birchenough with question Wells ahead. next Jim Please comes Our go Fargo. from

Jim Birchenough

guys. for the Yes. questions. just questions. Thanks Hi follow-up to taking on Hartaj's And

into forward an just, saw move would a first you efficacy Phase you guess I So only signal. adequate you if X mentioned Dayton,

So prospectively are in dose the of Could activity you you are you about could thinking that? some the patients are want see? to maybe you higher level What do parameters what looking for us at how that say or cohorts? you give

Dayton Misfeldt

Thanks Jim. Yes.

to move we So responses to partial forward. see would like multiple

have be the fleshed is will The profile this So what but seen the really, out more true we X. than part. X in Phase Phase

Jim Birchenough

of, you have into as cohorts to from have just, Could seven? cohorts it's Judy, were you five? and alluded increases seeing and Cmin seven, before you not, given you it, the give question cohort and give you maybe if are exp maybe going one in to then CCLX five fashion CCLX And for those could a gone levels five. a But from you it And and linear for if to so up escalation Judy. as sense also through seeing six cohort with dose in you one six still

Judy Fox

Yes.

as give are will with data, as XXX what saw And when more we we what have milligram cohort. assessment far the consistent data is we seeing the the new the XXX complete from milligram certainly So we cohort. in response PK then chemokines,

Jim Birchenough

So consistent chemokine increase consistent or levels?

Judy Fox

the important in consistent -- chemokine So decreases we saw

Jim Birchenough

Sorry.

Judy Fox

Yes.

Sorry, yes.

consistent So decreases.

Jim Birchenough

final one evidence cohorts indicator you and one. early of seven just then seen activity? And as any an of lymphocytosis Have six in

Judy Fox

No.

I We at prepared what past are comment I that's we and can think in the on to so point this don't think haven't time on that Yes, commented in it. say. I

Dayton Misfeldt

data. data. and the Jim, focused what to focused at this on cohort. just And clinical are Yes. presented so and milligram month have we really we been the the milligram indicators we going stopped we XXX XXX have soon early thereafter the have really the looking then The have cohort data, on data on and

Jim Birchenough

milligram meeting, that data focus are the you medical or going given you that, the going one, about hear cohort XXX to hear we the we on it? seeing a would saw to dose a for just reserve are at it on to PR, about And if time

Dayton Misfeldt

Yes.

the provide receive to going definitely are we it. as data We

meeting. don't an share so do And so, plan we going are to the find and with waiting this do I for way And XXX, yes. to will medical we to month be we similarly appropriate think a it

going that out are We data to to get folks. want to

Jim Birchenough

for taking the Great. Okay. questions. Thanks

Dayton Misfeldt

Thanks Jim.

Operator

Instructions]. you. Thank [Operator

Our Please next question from with will come go Frahm Cowen. Marc ahead.

Marc Frahm

us Is that? part Hi. taking to of things for have can these CLL earlier Are questions. have of the been Thanks on mutational enrollment? bit mutations, information PLC-gamma status to some little given provide that positive? questions. may you the my you Do patients CXXXS just as of the of kind on there they baseline follow-up Maybe patients, any a the like

Judy Fox

Yes.

So milligram cohort in a cohort milligram and the I with can tell XXX one CXXXS in that one mutation. mutations XXX had of the CXXX, patient a the mutation CXXXR two CXXXS a CLL we you patients, and and have

Marc Frahm

then Thanks. us maybe cash vecabrutinib and with the potentially the for in into just of cash terms in where balance, is Great. guess And right. help All clinic? runway what's XXX progressing Willie, assumed there I and getting there

Willie Quinn

Sure.

have million. cash the the end at We the year, was account million. balance restricted of as of said, $XX.X $X.X do So we a cash

in million, activities, million. used essentially usable cash $XX And million. in is $XX was it cash the XXXX if So think the XXXX in was you it $XX.X operating about

of cash for said, burn. the order quarter, can from being upfront our magnitude benefit fourth million historical a for the in the activities, we from you So payment That this TAK-XXX did $X sense license. get

that operating Without into taken for was expense $X.X million. fourth quarter the account,

after So dose have as do move and through that in expect cash the range. some spend financing we preparatory SNS-XXX burn the long burn guidance are get up. it's to would self-regulating And have X we to not to little million in that and escalation our we this of escalation to giving are to million $X.X as go forward. move that a the are $X in extent, dose we likely a And the runway is activities in but Phase in terms phase, IND to specific we to only

Marc Frahm

Okay. for the questions. Great. answering Thanks

Willie Quinn

Thanks Marc.

Operator

I this no back am time. like at over Thank you. call I remarks. now showing further in further queue questions management for would to the any

Dayton Misfeldt

very good you participating signs for XXX second patient demonstrated and look month assessments clinical our population. Thank We everyone this safety sick on further of vecabrutinib afternoon. on today. and the activity forward the call to milligram in early a and has response good you a Thank details update We believe in later quarter. providing

Operator

conference Ladies and Thank gentlemen, for concludes you today's this participation. call.

disconnect. now may You

Viracta Therapeutics (VIRX) 10 Mar 202019 Q4 Earnings call transcript